On Politics and Prognostications
That didn't take long. In mid-December, we released a short video that summarized a few items of interest from 2018. We also offered a few predictions for 2019. One of…
Menu
Industry Concentration: Real or Myth?
Somewhere in the deep recesses of our collective memory, the Concentration Ratio resides. It's a quick measure of how competitive an industry is. You can read all about it here. …
BIO Report: Type II Diabetes and Obesity
Good stuff... BIO recently published their latest report characterizing innovation in highly prevalent, chronic diseases. A full list of past reports is available here. They are short, data-rich, and quite…
Can CrossFit Change The Practice of Medicine?
Back during our early days as an Analyst with a venture capital fund, one of the Managing Partners always asked a simple question when assessing opportunities: "Will this change the…
Can AI Revolutionize Business Development?
Want to spend an entire decade surfing the web? Try finding and reading every article on “artificial intelligence.” A serious branch of computer science has rapidly turned into a buzzword…
Licensing versus Fund Raising Presentations: What’s the difference?
Congrats on beginning your quest towards the Holiest of Grails in our industry...capital. Your Board has given you a "simple" mandate: Find an investor or a licensing partner for the…
Good Article: Strategic Alliances Between Int’l Stakeholders
The August Edition of Life Science Leader has a summary of a panel discussion. The article is available here, and is well worth the time to read it if you…
2018 Pipeline Review
The good folks at Pharmaprojects just published their Pharma R&D Annual Review. A summary of the report, plus a link to the full report, is available here. The report…
Opioids – Nobody Wins
Two months ago, it was reported that six US states filed lawsuits against Connecticut-based Purdue Pharma, accusing the company of “...fueling a national opioid epidemic by deceptively marketing its prescription painkillers...”…
The PYS Problem
At Lacerta Bio, we see a lot of financial models and valuations. Some of these are prepared internally, obviously. But many are prepared by management teams as part of…
- Go to the previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- …
- 32
- Go to the next page